DE-THE-LYCRA-COMPANY
8.10.2021 01:02:08 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel and personal care industries, today announced wins related to its ongoing global efforts to protect its intellectual property (IP), including patents and trademarks, from infringement worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211007005014/en/
The LYCRA Company recently initiated several infringement suits related to its dual core and multi-core patents for denim against third parties in China. These third parties were selling fibers and goods The LYCRA Company deemed to infringe on LYCRA® brand patents.
The Chinese National Intellectual Property Administration (CNIPA) has recently issued a formal decision in support of The LYCRA Company patents for two invalidity challenges. Subsequently, the Jiangsu Authority has informed The LYCRA Company that its patent has been upheld in both these cases.
“We are pleased with the outcome of these two cases with our patents being recognized and upheld by the Chinese authorities,” said Bridget Sciamanna, general counsel for The LYCRA Company. “Protecting our patents and trademarks is a key strategic priority for us in safeguarding the value of our global brands.”
Supporting Customers in Patent Infringement Actions
The LYCRA Company is proud to offer its customers and licensees unmatched support in patent challenges related to its products. In two recent cases, two licensees in Europe turned to The LYCRA Company for technical and legal assistance for their own patent litigation defenses related to the company’s dual core patents. This assistance helped bring about wins for the licensees against the challenger. The presiding court ruled the licensees were not infringing on the other company’s patent.
Fighting Trademark Infringement
As part of its ongoing effort to combat misuse and trademark infringement of its brands globally, The LYCRA Company actively searches online marketplaces to find listings for fabrics and garments that attempt to capitalize on its brands’ positive reputations to drive sales, despite its products not being used.
Only fabrics and garments that have been tested and certified by The LYCRA Company to confirm they contain its fibers and meet its brands’ performance standards are eligible to use its trademarks. Over the past 12 months, the company has successfully removed 2,400 website listings and over 800 social media profiles and posts that infringed on its trademarks.
One of the marketplace websites, a major ecommerce platform in China, immediately acted to correct or take down any listings by third party sellers with trademark infringement issues flagged by The LYCRA Company.
“When our brand names are used on inferior products, it not only damages the consumer’s perception of our brands, it can also diminish the value of a customer's investment in our products,” said Julien Born, ceo of The LYCRA Company. “We have significantly invested in innovation, branding, and marketing for decades, so we will always fight to protect and defend our intellectual property to the fullest extent of the law.”
In the past year, The LYCRA Company has been granted 52 patents globally for innovations across a range of technologies, including new polymers, fabric constructions, stretch and performance technologies, as well as processes for apparel and hygiene applications.
To learn more about LYCRA® brand trademarks, click here .
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit thelycracompany.com .
LYCRA® is a trademark of The LYCRA Company
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom